Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant α-interferon

Journal of Viral Hepatitis

Volumn 7, Issue 1, 2000, Pages 75-78

  Bresci, G ^a,b   Parisi, G ^a   Bertoni, M ^a   Scatena, F ^a   Capria, A ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b NONE   (Italy)

Author keywords

Chronic hepatitis C; Interferon plus ribavirin; Interferon therapy; Non responders

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0034050325     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2000.00212.x     Document Type: Article

References (37)

1. 1 Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B, hepatitis with recombinant human alpha IFN. A preliminary report. N Engl J Med 1986; 315: 1575-1578.
2. 2 Tine F, Magrin S, Craxi A, Pagliaro L. Alpha-IFN in non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192-199.
3. 3 Malaguarnera M, Restuccia S, Trovato G et al. IFN-α treatment in patients with chronic hepatitis C. a meta analytic evaluation. Clin Drug Invest 1995; 9: 141-149.
4. 4 Ryff JC. Usefulness of IFN for treatment of hepatitis C. J Hepatol 1995; 22: 101-109.
5. 5 Poynard T, Leroy V, Marielle C et al. Meta-analysis of IFN randomized trials in the treatment of viral hepatitis C. Effects dose duration. Hepatology 1996; 24: 778-789.
6. 6 Hoofnagle J. The treatment of chronic viral hepatitis. N Engl J Med 1997; 5: 336-356.
7. 7 Camma C, Giunta M, Linea C, Pagliaro L. The effect of IFN on the liver in chronic hepatitis C. A quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26: 1187-1199.
8. 8 Schalm SW, Brouwer JT. Antiviral therapy of hepatitis C. Scand J Gastroenterol 1997; 223: 46-49.
9. 9 Toyoda H, Nkano S, Takeda I et al. Retreatment of chronic hepatitis C with IFN. Am J Gastroenterol 1994; 89: 1453-1457.
10. 10 Marriott E, Quiroga JA, Carrero V et al. Retreatment of chronic hepatitis C with IFN. J Infect Dis 1992; 166: 1200-1201.
11. 11 Carrero V, Marriot E, Quiroga JA et al. Other approaches to the treatment of chronic viral hepatitis. J Hepatol 1993; 17 (Suppl.): 127-129.
12. 12 Marcellin P, Boyer N, Pouteau M et al. Retreatment with IFN alpha of chronic hepatitis C virus infection. Lancet 1994; 344: 690-691.
13. 13 Bresci G, Parisi G, Banti S, Capria A. Re-treatment of IFN-resistant patients with chronic hepatitis C with IFN-α. J Viral Hepat 1995; 2: 155-158.
14. 14 Gerken G, Teuber G, Goergen B et al. IFN alpha retreatment in chronic hepatitis. J Hepatol 1995; 22: 118-121.
15. 15 Bresci G, Parisi G, Banti S et al. Chronic hepatitis C. What treatment for non-responders to recombinant-IFN-α? Clin Drug Invest 1996; 11: 224-228.
16. 16 Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus IFN alfa for IFN alfa resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817.
17. 17 Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with IFN alfa-2b and ribavirin for chronic hepatits C in patients who have failed to achieve sustained response to IFN alone: Swedish experience. J Hepatol 1995; 23: 17-21.
18. 18 Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha IFN in the treatment of chronic active hepatitis C not responding to alpha-IFN alone. Ital J Gastroenterol 1996; 28: 505-511.
19. 19 Bellobuono A, Mondazzi L, Tempini S et al. Ribavirin and IFN-alpha combination therapy vs IFN-alpha alone in the treatment of chronic hepatitis C. A randomized clinical trial. J Viral Hepat 1997; 4: 185-191.
20. 20 Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of IFN in chronic hepatitis C. Meta-analysis of individual patients data from European centers. J Hepatol 1997; 26: 961-966.
21. 21 Bianchi L, De Groote J, Desmet VJ et al. Acute and chronic hepatitis revisited. Lancet 1977; ii: 914-919.
22. 22 Scheuer P. Liver Biopsy Interpretation, 3rd edn. London: Baillere Tindall, 1980: 102-132.
23. 23 Imberti L, Cariani E, Bettinardi A et al. An immunoassay for specific amplified HCV sequences. J Virol Methods 1991; 36: 233-243.
24. 24 Lee JH, Roth WK, Zeuzem S et al. Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. J Hepatol 1997; 26: 1001-9.
25. 25 Knodell RG, Ando Y, Sonnerborg A et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
26. 26 Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.
27. 27 Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948-963.
28. 28 Bresci G, Parisi G, Banti S, Bertoni M. Therapy of active chronic hepatitis with recombinant α2b-IFN. an 18 month follow-up. EJM 1993; 6: 349-352.
29. 29 Bresci G, Del Corso L, Giuliano G. The use of recombinant IFN alfa-2b in elderly patients with anti-HCV positive chronic active hepatitis. JAGS 1993; 41: 857-862.
30. 30 Bresci G, Gambardella L, Parisi G et al. Sustained remission and viremia in chronic hepatitis C treated with recombinant α-IFN. Int J Clin Pharm Res 1995; 5: 175-179.
31. 31 Schalm SW, Brouwer JT, Chemello L et al. IFN-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci 1999; 41: 131-134.
32. 32 Camps J, Cristomo S, Garcia-Granero M et al. Prediction of response of chronic hepatits C to IFN alfa: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-1717.
33. 33 Jouet P, Roudot-Thoraval F, Dhumeaux D et al. Comparative efficacy of IFN alfa in cirrhotic and non cirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686-690.
34. 34 Pagliaro L, Craxì A, Cammà C et al. IFN-alfa for chronic hepatitis C. An analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-828.
35. 35 Milella M, Santantonio T, Pietromatera G et al. Reteatment of non-responders or relapser chronic hepatitis C patients with IFN plus ribavirin vs IFN alone. Ital J Gastroenterol Hepatol 1999; 31: 211-215.
36. 36 Bellobuono A, Mondazzi L, Tempini S et al. Ribavirin and IFN-alpha combination therapy vs IFN-alpha alone in the retreatment of chronic hepatitis C. A randomized clinical trial. J Viral Hepat 1997; 4: 185-191.
37. 37 Andreone P, Gramenzi A, Cursaro C et al. IFN-alpha plus ribavirin in chronic hepatitis C resistant to previous IFN-alpha course: results of a randomized multicenter trial. J Hepatol 1999; 30: 788-793.